Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection

Li-Ting Yan, MMa,b, Li-Li Wang, MDc, Jia Yao, MD, PhD,e, Ya-Ting Yang, MMa,b, Xiao-Rong Mao, MD, PhD, Wei Yue, MMa, Yong-Wu Mao, MMa, Wei Zhou, MMa, Qing-Feng Chen, MMb, Yu Chen, MD, PhDf, Zhong-Ping Duan, MD, PhD, Jun-Feng Li, MD, PhDa,b,*

Abstract
Although serum bile acids and total cholesterol (TC) are closely related to liver cirrhosis, the potential diagnostic value of total bile acid-to-cholesterol ratio (TBA/TC) for liver fibrosis is unclear. The present study aimed to evaluate the value of TBA/TC in the diagnosis of cirrhosis and the relationship between TBA/TC and significant liver fibrosis in chronic hepatitis B virus (HBV) infected patients without cholestasis.

667 patients with alkaline phosphatase (ALP) ≤ 1.5 upper limit of normal (ULN) and gamma-glutamyl transferase (GGT) ≤ 3 ULN were rigorously included in this cross-sectional study. Liver biopsy was performed in 32 patients and METAVIR scoring system was used to evaluate liver fibrosis stage. Liver ultrasound elastography was performed in 138 patients, significant fibrosis was defined as fibrosis ≥ F2. Multiple logistic regression as well as receiver operating characteristic (ROC) curves analyses were performed.

Compared to patients with non-cirrhosis, TBA and TBA/TC were significantly higher in cirrhosis while TC was significantly lower (all P < .001). In multivariate analysis, TBA/TC was also independently associated with cirrhosis [odds ratio (OR) = 1.102, 95% confidence interval (CI): 1.085–1.166]. The area under the curve (AUC) of TBA/TC (0.87) was almost equivalent to the aspartate aminotransferase to platelet ratio index (APRI, AUC = 0.84) and fibrosis 4 score (FIB-4, AUC = 0.80), and the optimal cut-off value for TBA/TC to diagnose cirrhosis was 2.70. Among the patients performed liver biopsy, TBA/TC were significantly higher both in significant fibrosis and cirrhosis as well as significantly correlated with fibrosis stage (all P < .001). Furthermore, in patients performed liver ultrasound elastography, TBA/TC was also independently associated with significant fibrosis (OR = 1.040, 95% CI: 1.001–1.078).

Assessment of TBA/TC could serve as an additional marker of significant liver fibrosis and cirrhosis in non-cholestatic chronic HBV infection.

Abbreviations: ALB = albumin, ALP = alkaline phosphatase, ALT = alanine aminotransferase, APRI = aspartate aminotransferase to platelet ratio index, AST = aspartate aminotransferase, AUC = area under the curve, BAs = bile acids, CHe = cholinesterase, CI = confidence interval, FIB-4 = fibrosis 4 score, GGT = gamma-glutamyl transferase, HBV = hepatitis B virus, OR = odds ratio, PPV = positive predictive value, PTA = prothrombin activity, ROC = receiver operating characteristic, TBA/TC = total bile acid-to-cholesterol ratio, TBIL = total bilirubin, TC = total cholesterol, ULN = upper limit of normal.

Keywords: bile acids and salts, cholesterol, hepatitis B virus, liver cirrhosis
1. Introduction

Chronic hepatitis B virus (HBV) infection affects an estimated 240 million persons worldwide,[1] making these patients at a high risk of developing cirrhosis, hepatic decompensation, and hepatocellular carcinoma.[2] Early diagnosis and intervention of liver fibrosis staging is essential. Currently, liver biopsy is considered as the ‘gold standard’ for determining the fibrosis.[3] However, liver biopsy is limited due to high sampling error and potential complications as an invasive examination.[3,4] Thus, noninvasive methods to assess the severity of hepatic fibrosis in chronic HBV infection is particularly needed, especially in resource-limited settings.

Several noninvasive fibrosis tests based on ultrasound principles or serum indicators are now available. Transient elastography (FibroScan) has been reported to accurately reflect liver fibrosis.[5] But the feasibility and reproducibility of the test may be affected by high body mass index.[6,7] In addition, the cost of acquiring, running and maintaining FibroScan is relatively high.[8] Serum indicators are simple and inexpensive noninvasive methods. Among them, aspartate aminotransferase to platelet ratio index (APRI) and fibrosis index based on the 4 factors (FIB-4) are recommended by clinical practice guidelines as commonly used indicators for evaluating liver fibrosis.[8,9] However, APRI and FIB-4 were initially used to diagnose hepatic fibrosis in patients with chronic hepatitis C and in patients co-infected with human immunodeficiency virus and hepatitis C virus respectively.[10,11] The sensitivity and specificity of these two noninvasive indexes for detection of cirrhosis were low,[8,12] and their application in chronic HBV infected patients is controversial.[13,14]

Therefore, new noninvasive markers for predicting fibrosis stage may reduce the need for liver biopsy. According to the current researches, serum bile acids (BAs) and lipid metabolism have a close relationship with liver diseases.[15-18] Among them, total cholesterol (TC) is independently correlated with the mortality of cirrhosis and BAs is a valuable prognostic index for cirrhosis.[19,20] A combination of fasting and postprandial BAs measurements appear to be more sensitive for detection of cirrhosis in patients with normal transaminases than other biochemical tests of liver function.[16] While in patients with HBV infection, TBA and HBV have a co-receptor when entering hepatocytes.[21] Binding of HBV to its cellular receptor affects the metabolism of BAs.[22] Since BAs are synthesized from cholesterol in hepatocytes and BAs metabolism plays an essential role in cholesterol homeostasis,[23] the abnormal of serum BAs levels may cause imbalance of BAs to cholesterol ratio.

In addition, the accumulation of serum BAs were also reported to be the main characteristic of cholestatic liver diseases that lead to necrosis and apoptosis of hepatocytes as well as progress of fibrosis.[24-26] The potential ability of the indicators related to BAs metabolism to differentiate non-cholestatic liver fibrosis has rarely been studied before. Therefore, the main purpose of the present study was to evaluate the value of total bile acid-to-cholesterol ratio (TBA/TC) in the diagnosis of liver fibrosis in chronic HBV infected patients without cholestasis. Based on a consecutive cohort, all subjects with serum alkaline phosphatase (ALP) > 1.5 upper limit of normal (ULN) and gamma-glutamyl transferase (GGT) > 3 ULN or with primary biliary cirrhosis, primary sclerosing cholangitis, obstructive jaundice and cholangiocarcinoma were strictly excluded. After eliminating the interference of cholestasis, the relationship between TBA/TC and liver fibrosis was truly reflected, and the true and convincing results of diagnostic value of TBA/TC for liver cirrhosis could be acquired based on our cohort.

2. Material and methods

2.1. Patients

A group of 667 consecutive chronic HBV infected patients from the first hospital of Lanzhou university were included from June 2016 to August 2017. Figure 1 summarized the flow diagram of the study population, and the inclusion criterion was the persistence of hepatitis B surface antigen for more than 6 months.[2,8] Identifying persons with cirrhosis was made by histological or combination of clinical signs (hepatomegaly and splenomegaly, ascites, caput medusa, spider naevi and others) and laboratory parameters or typical liver imaging signs (typical morphological changes of liver, portal hypertension signs in abdominal ultrasonography or computed tomography).[3] Clinical features of compensated cirrhosis include Portal hypertension (ascites, variceal hemorrhage of esophageal or gastric and hepatic encephalopathy), coagulopathy, or liver insufficiency.[3] In addition, significant hepatic fibrosis was determined by liver ultrasound elastography.[27]

The exclusion reasons were as follows:

1. less than 18 years old;
2. insufficient clinical data (without hemocyte, liver chemistry and coagulation indicators);
3. acute hepatitis B;
4. combined with other liver diseases (hepatitis A, hepatitis C, hepatitis E, autoimmune hepatitis, alcoholic liver disease, steatohepatitis, drug-induced liver injury, Wilson’s disease or metastatic liver cancer);
5. co-infected with HIV;
6. received liver transplantation or plasmapheresis;
7. hepatocellular carcinoma received transcatheter arterial chemoembolization or radiofrequency ablation;
8. with extrahepatic solid tumors received radiotherapy or chemotherapy;
9. use of immune inhibitors, hepatotoxic drugs, ursodeoxycholic acid;
10. co-existence of other serious diseases (shock, multiple organ failure, uremia and required dialysis, severe infection, hematologic malignancies);
11. with cholestasis. Cholestasis is defined as serum ALP > 1.5 ULN and GGT > 3 ULN,[28] the ULN of ALP and GGT are 125U/L and 69U/L respectively. The patients with primary biliary cirrhosis, primary sclerosing cholangitis, obstructive jaundice and cholangiocarcinoma were also excluded.

The present study was anonymously analyzed and met the ethical requirements of the institutional review boards at the first hospital of Lanzhou university (Approval number: LDYYLL2019–211).

2.2. Laboratory tests

Serum hematological and fasting biochemical parameters within 24 hours of admission were tested. For patients performed liver biopsy, blood samples were collected before invasive operation. Haematological indicators, including white blood cell counts, lymphocyte, neutrophil, red blood cell counts, hemoglobin and platelet counts, were tested by fully automatic blood cell analyzer.
Biochemical parameters, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), ALP, GGT, total bilirubin (TBIL), direct bilirubin, indirect bilirubin, TBA, TC, triglyceride, total protein, albumin (ALB), globulin, cholinesterase (CHE), creatinine and urea nitrogen, were tested by fully automatic biochemical analyzer (Olympos AU400, Japan). Virological parameters of HBV included hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B e antigen and HBV DNA.

APRI, FIB-4 were calculated as previously described: APRI = \( \frac{\text{AST (U/L)/its ULN}}{\text{PLT (10^9/L)}} \times 100 \) and FIB-4 = \( \frac{\text{Age (years) × AST (U/L)}}{\text{PLT (10^9/L) × [ALT (U/L)]^{1/2}}} \) respectively.

### 2.3. Liver biopsy and histological examination

Liver biopsies were performed using ultrasound localization. Each specimen was longer than 1.5cm, containing at least 6 complete portal area. The samples were formalin-fixed and paraffin-embedded for histological analysis. Hepatic histology was interpreted by two senior pathologists who were blinded to the patients’ clinical information. Hepatic fibrosis stage was assessed according to the METAVIR scoring system from F0 to F4: F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with few septa; F3, numerous septa without cirrhosis; and F4 was considered as cirrhosis.[29]

### 2.4. Statistical analysis

Statistical analysis was performed using SPSS version 17.0 (Chicago, IL). Continuous variables were presented as mean ± standard deviation, categorical values were expressed as frequencies. Data distribution were analyzed according to the Kolmogorov-Smirnov test. The differences of normally distributed data were analyzed using two-independent samples t test, non-normally distributed data were analyzed using Mann-Whitney test. Correlation analysis was evaluated using Spearman’s rank correlation. The (LR) multivariate logistic regression analysis with stepwise forward selection was performed to identify predictors of cirrhosis and significant liver fibrosis, the P values of entry and removal were respectively set to .05 and .10. The diagnostic value of independent predictors were assessed according to the area under the receiver operating characteristic (ROC) curves and 95% confidence interval (CI). Sensitivity analyses were performed using MedCalc version 18.2 software (MedCalc Software, Mariakerke, Belgium). A two-sided P < .05 was considered statistically significant.

### 3. Results

#### 3.1. Patient characteristics

A group of 667 chronic HBV infected patients without cholestasis were included and the characteristics of included participants were shown in Table 1. The mean age was 48.80±11.00 years and the proportion of men was 63.87%.

The progression stages of chronic HBV infection were divided into three parts: 216 patients (32.38%) without cirrhosis, 156 (23.39%) patients with compensated cirrhosis and 295 (44.23%) patients with decompensated cirrhosis. Among the 32 patients who performed liver biopsy, F4 accounted for the largest proportion (23/32, 71.87%), this was followed by F1-F3 (9), and F4 (23).

### Figure 1. Flow diagram of the study population. HBV=hepatitis B virus, HCC=hepatocellular carcinoma, HIV=human immunodeficiency virus.
Table 1
Baseline characteristics of the included patients.

| Parameter                    | Value               |
|------------------------------|--------------------|
| Age (years)                  | 48.82 ± 11.00      |
| Male, n (%)                  | 426 (63.87)        |
| WBC × 10^9/L                 | 4.67 ± 2.38        |
| RBC × 10^12/L                | 4.31 ± 2.02        |
| Hb (g/L)                     | 130.93 ± 28.43     |
| PLT (× 10^9/L)               | 109.78 ± 71.47     |
| AST (U/L)                    | 65.63 ± 101.32     |
| ALT (U/L)                    | 61.65 ± 107.83     |
| ALP (U/L)                    | 111.95 ± 43.75     |
| GGT (U/L)                    | 54.20 ± 55.21      |
| TBIL (μmol/L)                | 30.93 ± 53.49      |
| DBL (μmol/L)                 | 17.62 ± 50.77      |
| IBL (μmol/L)                 | 26.32 ± 30.90      |
| TBA (μmol/L)                 | 35.58 ± 63.10      |
| TC (mmol/L)                  | 3.35 ± 1.03        |
| TG (mmol/L)                  | 1.06 ± 0.17        |
| TP (g/L)                     | 68.90 ± 9.47       |
| ALB (g/L)                    | 39.92 ± 6.64       |
| CHE (KU/L)                   | 5.11 ± 2.32        |
| PT (s)                       | 14.32 ± 4.47       |
| PTA (%)                      | 75.95 ± 21.94      |
| APTT (s)                     | 35.92 ± 10.34      |
| HbAky (+), n (%)             | 247 (37.03)        |
| Asletes, n (%)               | 196 (29.30)        |
| Esophageal or gastric varices, n (%) | 288 (45.03) |
| Hepatic encephalopathy, n (%) | 19 (2.84)          |

F3 were accounted for 6.25% (2/32) and 9.38% (3/32) respectively. Liver histological stages were divided into two groups of non-cirrhosis (F1-F3) and cirrhosis (F4).

In addition, 138 patients performed liver ultrasound elastography. F2 was presented in 70 patients, which accounted for the largest proportion (50.72%). This was followed by F1 (31.89%) and F0 (7.97%). F3 and F4 were found in 5.80% and 3.62% of the patients respectively.

3.2. TBA/TC as a serum marker for cirrhosis in chronic HBV infected patients without cholestasis

Compared to patients without cirrhosis, TBA, TBA/TC, AST, ALT, ALP, GGT and TBL were significantly higher in cirrhosis, while TC, ALB, CHE and prothrombin activity (PTA) were significantly lower (Table 2, all P < .001), which were all significantly correlated with the progression stages of chronic HBV infection (all P < .001, as shown in Table 3. Subsequently, indicators related to bile excretion, including TBL, ALP, GGT, TBTC, were entered into multivariate analysis. The selection of variables adopted stepwise forward procedures and the final results were shown in Table 4. TBTC has a larger OR value (OR = 1.102, 95% CI: 1.085–1.166) than ALP (OR =

Table 2
Indicators of cirrhosis in chronic hepatitis B virus infected patients without cholestasis.

| Parameter                  | Non-cirrhosis (n = 216) | Cirrhosis (n = 451) | P  |
|----------------------------|-------------------------|---------------------|----|
| Age (years)                | 49.79 ± 12.74          | 48.33 ± 10.04       | .005|
| WBC × 10^9/L               | 5.92 ± 2.31            | 4.07 ± 2.18         | < .001|
| RBC × 10^12/L              | 4.89 ± 3.27            | 4.03 ± 0.84         | < .001|
| Hb (g/L)                   | 143.86 ± 83.20         | 124.74 ± 28.65      | < .001|
| PLT (× 10^9/L)             | 166.34 ± 61.53         | 82.69 ± 58.99       | < .001|
| AST (U/L)                  | 52.79 ± 87.24          | 71.78 ± 106.96      | < .001|
| ALT (U/L)                  | 59.65 ± 110.70         | 62.61 ± 106.53      | < .001|
| ALP (U/L)                  | 96.24 ± 31.05          | 119.47 ± 46.87      | < .001|
| GGT (U/L)                  | 40.32 ± 47.17          | 60.68 ± 57.54       | < .001|
| TBIL (μmol/L)              | 23.71 ± 30.70          | 53.49 ± 89.16       | < .001|
| TBA (μmol/L)               | 12.36 ± 35.05          | 46.70 ± 70.16       | < .001|
| TC (mmol/L)                | 3.98 ± 0.66            | 5.66 ± 1.04         | < .001|
| TP (UL)                    | 68.49 ± 8.45           | 67.89 ± 9.92        | .425 |
| ALB (g/L)                  | 43.17 ± 4.73           | 38.37 ± 6.86        | < .001|
| CHE (KU/L)                 | 6.92 ± 1.95            | 4.24 ± 1.97         | < .001|
| PTA (%)                    | 91.67 ± 15.85          | 68.40 ± 20.41       | < .001|
| TBTC                        | 3.91 ± 14.12           | 27.42 ± 75.64       | < .001|

Table 3
Correlation analysis between laboratory indicators and different degrees of liver fibrosis in chronic hepatitis B virus infected patients without cholestasis.

| Parameter                  | Progression stages ( n = 667) | F1, F2, F3, F4 (liver biopsy, n = 32) |
|----------------------------|--------------------------------|--------------------------------------|
|                            | r     | P         | r     | P         |
| PLT (× 10^9/L)             | −0.60 | < .001    | −0.63 | < .001    |
| ALB (g/L)                  | −0.49 | < .001    | −0.64 | < .001    |
| CHE (KU/L)                 | −0.66 | < .001    | −0.64 | < .001    |
| PTA (%)                    | −0.66 | < .001    | −0.51 | < .001    |
| AST (U/L)                  | 0.38  | < .001    | 0.25  | .199      |
| ALT (U/L)                  | 0.21  | < .001    | 0.09  | .627      |
| ALP (U/L)                  | 0.24  | < .001    | 0.04  | .827      |
| GGT (U/L)                  | 0.18  | < .001    | 0.01  | .938      |
| TBL (μmol/L)               | 0.49  | < .001    | 0.25  | .173      |
| TBIL (μmol/L)              | 0.63  | < .001    | 0.57  | < .001    |
| TC (mmol/L)                | −0.50 | < .001    | −0.65 | < .001    |
| TBTC                        | 0.67  | < .001    | 0.62  | < .001    |

Table 4
Correlation analysis between laboratory indicators and different degrees of liver fibrosis in chronic hepatitis B virus infected patients without cholestasis.
Table 4
Predictors of cirrhosis according to multiple logistic regression analysis.

| Parameter | Non-cirrhosis | Cirrhosis | OR     | 95%CI     | P    |
|-----------|---------------|-----------|--------|-----------|------|
| Total patients (n = 667) | | | | | |
| TBL (μmol/L) | 23.71 ± 30.93 | 53.49 ± 89.16 | | | |
| ALP (U/L) | 96.24 ± 31.05 | 119.47 ± 46.87 | 1.007 | 1.002–1.013 | .008 |
| GGT (U/L) | 40.32 ± 47.17 | 60.85 ± 57.54 | 1.007 | 1.002–1.011 | .003 |
| TBA (μmol/L) | 12.36 ± 35.05 | 46.70 ± 70.16 | | | |
| TBA/TC | 3.91 ± 14.12 | 27.42 ± 75.64 | 1.102 | 1.085–1.166 | <.001 |
| Patients with liver biopsy (n = 32) | | | | | |
| Age (years) | 46.44 ± 5.34 | 46.96 ± 11.28 | | | |
| ALB (g/L) | 47.02 ± 9.66 | 38.90 ± 7.73 | | | |
| CHE (KU/L) | 7.93 ± 1.00 | 4.45 ± 2.47 | | | |
| PTA (%) | 91.28 ± 24.51 | 69.66 ± 15.95 | | | |
| TBA (μmol/L) | 4.87 ± 4.37 | 23.02 ± 15.56 | | | |
| TBA/TC | 1.13 ± 0.38 | 9.19 ± 6.31 | 2.145 | 1.035–4.442 | <.001 |

ALB = albumin, ALP = alkaline phosphatase, CHE = cholinesterase, GGT = gamma-glutamyl transferase, PTA = prothrombin activity, TBA/TC = total bile acid-to-cholesterol ratio, TBA = total bile acid, TBL = total bilirubin.

1.007, 95% CI: 1.002–1.013) and GGT (OR = 1.007, 95% CI: 1.002–1.011).

Furthermore, among the patients performed liver biopsy, TBA and TBA/TC were significantly higher both in significant fibrosis and cirrhosis (all P < .001), and ALB (P = .009 and P < .001), CHE (both P < .001) and PTA (P = .028 and P = .006) were significantly lower, while TC was only significantly lower in cirrhosis (P < .001, Table 5). In the subsequent Spearman’s correlation analysis, significant correlations were also found between variables of TBA (r = 0.57, P = .001), TBA/TC (r = 0.62, P < .001), ALB (r = –0.64, P < .001), CHE (r = –0.64, P < .001), PTA (r = –0.51, P = .003) and the fibrosis stage of F1, F2 and F4 (Table 3). These five indicators together with age were then entered into the multivariate analysis. The results were shown in Table 4, and TBA/TC was found to be independently correlated with cirrhosis in chronic HBV infected patients without cholestasis (OR = 2.145, 95% CI: 1.035–4.442).

3.3. TBA/TC diagnoses cirrhosis in chronic HBV infected patients without cholestasis

To evaluate the ability of TBA/TC in diagnosing cirrhosis in non-cholestatic chronic HBV infected patients, the ROC curves and sensitivity analyses were performed comparing with APRI and FIB-4, as shown in Figure 2A and Table 6. The area under the curve (AUC) of TBA and TBA/TC were 0.85 and 0.87 respectively (all P < .001), which were almost equivalent to APRI and FIB-4 (AUC = 0.84, P < .001 and AUC = 0.80, P < .001, respectively). The sensitivity, specificity and positive predictive value (PPV) of FIB-4 (80.49%, 71.76%, 85.60%, respectively) for diagnosing cirrhosis were lower than APRI (86.03%, 73.61%, 87.20%, respectively). But the specificity and PPV of TBA (85.19%, 91.70%) and TBA/TC (83.33%, 91.10%) were higher than those of APRI. The optimal cut-off value of TBA and TBA/TC were 10.40 and 2.70 respectively.

Table 5
Indicators of significant fibrosis and cirrhosis in non-cholestatic chronic hepatitis B virus infected patients performed liver biopsy.

| Parameter | < F2 (n = 4) | ≥F2 (n = 28) | P      | < F3 (n = 9) | F4 (n = 23) | P      |
|-----------|--------------|-------------|--------|--------------|-------------|--------|
| Age (years) | 45.50 ± 5.97 | 46.18 ± 10.40 | .900 | 46.44 ± 5.34 | 45.96 ± 11.28 | .870 |
| WBC (×10^9/L) | 4.41 ± 1.45 | 3.51 ± 2.23 | .444 | 5.31 ± 1.76 | 2.97 ± 1.94 | .004 |
| RBC (×10^12/L) | 6.65 ± 6.2 | 4.04 ± 0.84 | .181 | 4.68 ± 0.47 | 3.83 ± 0.77 | .001 |
| Hb (g/L) | 119.79 ± 32.68 | 118.29 ± 35.76 | .939 | 144.11 ± 30.75 | 108.43 ± 31.58 | .007 |
| PLT (×10^9/L) | 203.29 ± 68.56 | 84.79 ± 75.15 | .017 | 180.00 ± 67.70 | 68.09 ± 66.76 | <.001 |
| AST (U/L) | 27.03 ± 7.74 | 48.49 ± 56.41 | .158 | 34.60 ± 20.31 | 50.19 ± 60.26 | .213 |
| ALT (U/L) | 26.45 ± 7.64 | 40.89 ± 36.82 | .819 | 46.21 ± 36.81 | 36.65 ± 34.30 | .536 |
| ALP (U/L) | 74.80 ± 13.95 | 101.76 ± 36.07 | .154 | 96.89 ± 28.28 | 98.97 ± 38.04 | .883 |
| GGT (U/L) | 19.58 ± 6.07 | 62.85 ± 80.00 | .082 | 83.50 ± 124.33 | 47.24 ± 46.36 | .417 |
| TBL (μmol/L) | 30.75 ± 34.32 | 27.33 ± 14.73 | .856 | 24.71 ± 22.94 | 28.95 ± 15.23 | .545 |
| TBA (μmol/L) | 5.23 ± 3.67 | 20.22 ± 16.02 | <.001 | 4.87 ± 4.37 | 23.62 ± 15.56 | <.001 |
| TC (mmol/L) | 3.92 ± 0.52 | 3.18 ± 1.09 | .201 | 4.39 ± 0.60 | 2.84 ± 0.86 | <.001 |
| TP (g/L) | 78.85 ± 4.65 | 68.06 ± 8.96 | .026 | 74.64 ± 6.39 | 67.36 ± 4.87 | .043 |
| ALB (g/L) | 48.70 ± 5.74 | 40.11 ± 5.95 | .009 | 47.02 ± 5.66 | 38.90 ± 5.73 | <.001 |
| CHE (KU/L) | 7.55 ± 0.21 | 5.13 ± 2.72 | <.001 | 7.93 ± 1.00 | 4.45 ± 2.47 | <.001 |
| PTA (%) | 96.83 ± 9.09 | 72.73 ± 20.32 | .028 | 91.28 ± 24.51 | 69.66 ± 15.95 | .006 |
| TBA/TC | 1.41 ± 1.02 | 7.71 ± 6.56 | <.001 | 1.13 ± 0.98 | 9.19 ± 6.31 | <.001 |

ALB = albumin, ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, CHE = cholinesterase, GGT = gamma-glutamyl transferase, Hb = hemoglobin, PLT = platelet counts, PTA = prothrombin activity, RBC = red blood cell counts, TBA/TC = total bile acid-to-cholesterol ratio, TBA = total bile acid, TBL = total bilirubin, TC = total cholesterol, TP = total protein, WBC = white blood cell counts.
Furthermore, among the patients performed liver biopsy, the AUC of TBA and TBA/TC were 0.87 ($P = .001$) and 0.91 ($P < .001$) respectively (Fig. 2B), which were also almost equivalent to APRI and FIB-4 (AUC = 0.87, $P = .002$ and AUC = 0.79, $P = .013$, respectively).

### 3.4. TBA/TC as a serum marker for significant liver fibrosis in chronic HBV infected patients without cholestasis

TBA/TC was independently correlated with cirrhosis in chronic HBV infected patients without cholestasis. Consequently, we analyzed the correlation between TBA/TC and significant liver fibrosis, as shown in Table 7. TBA/TC was significantly increased in significant liver fibrosis as well as significantly associated with the fibrosis stages from F0 to F4 (both $P < .001$). In the subsequent multivariate analysis, after adjusting other factors related to liver injury and metabolism, including AST, ALT, ALP, GGT, TBA/TC was also independently correlated with significant fibrosis (OR = 1.040, 95% CI: 1.001–1.078). The AUC of TBA/TC that distinguishes significant liver fibrosis was 0.70 ($P < .001$) as shown in Figure 3.

### 4. Discussion

BAs metabolism has a close relationship with cholestatic liver diseases. In the study, all chronic HBV infected patients with cholestasis were excluded. Based on our cohort of included consecutive patients, the present study, for the first time, analyzed the relationship between the imbalance of TBA/TC ratio and liver fibrosis. According to the results, TBA/TC might be a novel noninvasive marker of significant fibrosis and cirrhosis in chronic HBV infected patients without cholestasis.

Currently, there is growing evidence determines the close relationship between TBA and cirrhosis, for example, TBA correlated strongly with hepatic venous pressure gradient and serum TBA levels may be elevated in portal hypertension bypassing the liver uptake via portosystemic shunt and intrahepatic shunt. Since BAs metabolism plays an essential role in cholesterol homeostasis, the elevation of serum BAs levels may cause imbalance of TBA/TC ratio. However, the association between TBA/TC and liver cirrhosis in chronic HBV infected patients without cholestasis remains to be elucidated. In the present study, the univariate analysis showed that TBA was significantly increased in cirrhosis in chronic HBV infected patients, which was consistent with previous studies. In addition, TBA/TC was also significantly increased in cirrhosis and had an independent relationship with cirrhosis in non-cholestatic chronic HBV infected patients.

Of all noninvasive fibrosis tests based on serum indicators, APRI and FIB-4 are recommended by clinical practice guidelines.

---

Table 6

| Parameter                  | Sensitivity% | Specificity% | PPV       | NPV       |
|----------------------------|--------------|--------------|-----------|-----------|
| **Total patients (n = 667)** |              |              |           |           |
| TBA ($\mu$mol/L)           | 78.49        | 85.19        | 91.70     | 65.50     |
| TBA/TC                     | 81.37        | 83.33        | 91.10     | 68.20     |
| APRI                       | 86.03        | 73.61        | 87.20     | 71.60     |
| FIB-4                      | 80.49        | 71.76        | 85.60     | 63.80     |
| **Patients with liver biopsy (n = 32)** |       |              |           |           |
| TBA ($\mu$mol/L)           | 69.57        | 100.00       | 100.00    | 56.20     |
| TBA/TC                     | 78.26        | 100.00       | 100.00    | 64.30     |
| APRI                       | 86.96        | 77.78        | 90.90     | 70.00     |
| FIB-4                      | 73.91        | 77.78        | 89.50     | 53.80     |

APRI = aspartate aminotransferase to platelet ratio index, FIB-4 = fibrosis 4 score, TBA/TC = total bile acid-to-cholesterol ratio, TBA = total bile acid.
also a priority for antiviral therapy. [2,9] In our study, the results were found in liver biopsy patients. According to the results, APRI (73.61%, 87.20%) and FIB-4 (71.76%, 85.60%). Similar 91.70%) and TBA/TC (83.33%, 91.10%) were higher than those 0.80, respectively). But the specificity and PPV of TBA (85.19%, 91.70%) and TBA/TC (83.33%, 91.10%) were higher than those of APRI (73.61%, 87.20%) and FIB-4 (71.76%, 85.60%). Similar results were found in liver biopsy patients. According to the results, the combination of these 4 noninvasive indicators may help to better distinguish the presence of cirrhosis.

Apart from cirrhosis, the presence of significant liver fibrosis is also a priority for antiviral therapy.[2,9] In our study, the univariate and multivariate analyses showed that TBA and TBA/TC were significantly increased in significant fibrosis in patients performed liver ultrasound elastography and TBA/TC was also found to be one of independent predictors of significant fibrosis (OR = 0.97, 95% CI: 0.95–0.99).

The limitations of the present study are as follows: firstly, although the retrospective study has been rigorously designed, there was a lack of animal or cell-based research to further elucidate the underlying mechanism of the imbalance of TBA/TC ratio in non-cholestatic chronic HBV infection. Secondly, the study was predominantly retrospective so that we did not analyze the dynamic changes of serum TBA and TC levels in non-cholestatic patients, and long-term prognostic value was not evaluated. Prospective studies need to be performed to explain the value of TBA/TC in the assessment of prognosis.

In conclusion, the calculated novel noninvasive indicator of TBA/TC could serve as an additional marker to distinguish significant liver fibrosis and cirrhosis in non-cholestatic chronic HBV infected patients. Further prospective studies are needed to confirm our findings.

Acknowledgments
The authors acknowledge all the staff of the First Hospital of Lanzhou University who have completed the serum parameter test, imaging and liver biopsy examination.

Author contributions
Conceptionalization: Li-Ting Yan, Qing-Feng Chen, Yu Chen, Jun-Feng Li.
Data curation: Li-Ting Yan, Li-Li Wang, Jia Yao, Ya-Ting Yang, Yong-Wu Mao.
Formal analysis: Li-Ting Yan, Jun-Feng Li.
Funding acquisition: Zhong-Ping Duan, Jun-Feng Li.
Investigation: Li-Ting Yan, Jia Yao, Ya-Ting Yang, Wei Yue, Yong-Wu Mao.
Methodology: Li-Li Wang, Xiao-Rong Mao, Wei Zhou, Qing-Feng Chen.
Project administration: Xiao-Rong Mao, Yu Chen, Zhong-Ping Duan, Jun-Feng Li.
Resources: Li-Li Wang, Ya-Ting Yang, Wei Yue, Wei Zhou.
Supervision: Xiao-Rong Mao, Zhong-Ping Duan, Jun-Feng Li.
Validation: Jia Yao, Qing-Feng Chen, Yu Chen, Zhong-Ping Duan.
Writing – original draft: Li-Ting Yan, Li-Li Wang, Jia Yao.
Writing – review & editing: Jun-Feng Li.

References
[1] Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212–9.
[2] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatology Int 2016;10:1–98.
[3] Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495–500.
[4] Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614–8.
[5] Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010;53:1013–21.
[6] Requill C, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968–73.
[7] Foucher J, Castera L, Bernard PH, et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol 2006;18:411–2.
[8] Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization; 2015.
[9] Terrault NA, Bzowoy NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261–83.
[10] Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–26.
[11] Tzarg RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317–25.
[12] Zhu MY, Zou X, Li Q, et al. A novel noninvasive algorithm for the assessment of liver fibrosis in patients with chronic hepatitis B virus infection. J Viral Hepat 2017;24:589–98.
[13] Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol 2016;64:773–80.
[14] Wang H, Xue L, Yan R, et al. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat 2013;20:e3–10.
[15] Festa D, Morcelli Labate AM, Roda A, et al. Diagnostic effectiveness of serum bile acids in liver diseases as evaluated by multivariate statistical methods. Hepatology 1983;3:707–13.
[16] Mannes GA, Stellato T, Paumgartner G. Increased serum bile acids in cirrhosis with normal transaminases. Digestion 1982;25:217–21.
[17] Neale G, Lewis B, Weaver V, et al. Serum bile acids in liver disease. Gut 1971;12:145–52.
[18] Zhang JY, Qu F, Li JF, et al. Up-regulation of Plasma Hexosylceramide (d18: 1/18: 1) contributes to Genotype 2 virus replication in chronic hepatitis C: A 20-year cohort study. Medicine (Baltimore) 2016;95:e3773.
[19] Janicko M, Veseliny E, Lesko D, et al. Serum cholesterol is a significant and independent mortality predictor in liver cirrhosis patients. Ann Hepatol 2013;12:581–7.
[20] Mannes GA, Thiene C, Stellato T, et al. Prognostic significance of serum bile acids in cirrhosis. Hepatology 1986;6:50–3.
[21] Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012;1:e00049.
[22] Oehler N, Volz T, Bhadra OD, et al. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. Hepatology 2014;60:1483–93.
[23] De Fabiani E, Mitro N, Gilardi F, et al. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 2003;278:39124–32.
[24] Dyson JK, Hirschfeld GM, Adams DH, et al. Novel therapeutic targets in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol 2015;12:147–58.
[25] Eaton JE, Talwalkar J, Lazzaridis KN, et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013;145:521–36.
[26] Hirschfeld GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010;139:1481–96.
[27] Cosgrove D, Pascaglia F, Rambler J, et al. ESUMF guidelines and recommendations on the clinical use of ultrasound elastography. Part 2: Clinical applications. Ultraschall Med 2013;34:238–53.
[28] Liver EARNet. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237–47.
[29] Bedossa P, Poyrand T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–93.
[30] Houvitsis T, Drola A, Roedl K, et al. Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis. Liver Int 2017;37:224–31.
[31] Lucy LK, Heaton KW. Bile acid clearance in liver disease. Gut 1979;20:1033–7.
[32] Reichen J, Egger B, Obara N, et al. Determinants of hepatic function in liver cirrhosis in the rat. Multivariate analysis. J Clin Invest 1988;82:2069–76.
[33] Thomas SH, Joh T, Benot JN. Role of bile acids in splanchic hemodynamic response to chronic portal hypertension. Dig Dis Sci 1991;36:1243–8.
[34] Gilmore IT, Thompson RP. Plasma clearance of oral and intravenous cholic acid in subjects with and without chronic liver disease. Gut 1980;21:123–7.
[35] Ohtsuki H, Okuda K, Iida S, et al. Role of portal and splenic vein shunts and impaired hepatic extraction in the elevated serum bile acids in liver cirrhosis. Gastroenterology 1984;86:514–20.
[36] Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007;46:32–6.
[37] Zhang Y, Wang R, Yang X. FIB-4 index serves as a noninvasive prognostic biomarker in patients with hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2018;97:e13696.
[38] Teshale E, Lu M, Rupp LB, et al. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHCoS). J Viral Hepat 2014;21:917–20.
[39] Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007;47:760–7.
[40] Kumar M, Sarin SK, Hissar S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008;134:1376–84.